MK2870-032: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Objective

Clinical Trial Details

Principal Investigator(s)
Alexandra (Ally) Higgins, MD

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Contact
Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org

Location

  • Avera Cancer Institute — Yankton
    1115 W 9th St
    Yankton, SD 57078
    Main: 605-668-8850
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000